Provectus Biopharmaceuticals (STU:PXY) Total Receivables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PXY Provectus Biopharmaceuticals Inc STU:PXY
35 GF Score
Price €0.05
! 3 Warning Signs
View Full Analysis

What is Provectus Biopharmaceuticals Total Receivables?

Provectus Biopharmaceuticals STU:PXY 35 Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:PXY with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Provectus Biopharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Provectus Biopharmaceuticals Total Receivables Related Terms

Provectus Biopharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Provectus Biopharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals Total Receivables Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Provectus Biopharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:PXY
35GF Score
Provectus Biopharmaceuticals Inc STU:PXY
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Provectus Biopharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
Provectus Biopharmaceuticals (STU:PXY) has a Total Receivables of €0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Provectus Biopharmaceuticals and its competitors.
Is Provectus Biopharmaceuticals' Total Receivables too high?
Provectus Biopharmaceuticals' current Total Receivables is €0.00 Mil. Overall, Provectus Biopharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Provectus Biopharmaceuticals' Total Receivables compare to PSTV and ALGS?
Provectus Biopharmaceuticals' Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (STU:PXY) has a current Total Receivables of €0.00 Mil. The current Total Receivables is €0.00 Mil. Provectus Biopharmaceuticals' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Provectus Biopharmaceuticals (STU:PXY), the current Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Other Exchanges PVCT:USA
Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
35GF Score

Get the complete analysis for STU:PXY

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price